Corrigendum

This article refers to:

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

Thomas Hunt, Nachum Kaplan, Barry Hafkin, “Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects”. Journal of Chemotherapy.

When the above article was first published, there were several errors in the text as follows:

In page 1, the affiliation 2,3 must be replaced with 2.

In page 1, the affiliation 3,4 must be replaced with 2.

In page 1, the affiliation should be change as Current addresses: NK: Nobelex Biotech, MaRS Centre, Toronto, Ont., Canada; BH: MicuRx Pharmaceuticals, Inc, Austin, TX, USA.

In page 1, in abstract we would prefer space between number and unit as is convention throughout the article. Refer to all units – mg, g and ng/ml.

In page 1, in abstract high fat should be changed to high-fat.

In page 1, in abstract twice a day should be changed to twice-daily.

In page 1, the keyword “Staphylococcus aureus” is added.

In page 1, immediate release should be changed to immediate-release.

In page 1, Multi dose has been removed and replace Multiple dose.

In page 1, in the text “activity, is not reduced in the presence of lung Surfactant” the “,” has been deleted.

In page 1, in the text “A Phase 1 study with AFN-1252 (a free base) in an immediate release (IR)” the “an” has deleted.

In page 1, in the text “PK of single ascending doses of 100–400 mg, administered once-daily (QD) or every 12 h” after this sentence add the word (twice-daily,BID).

In page 1, in the text “AFN-1252 was rapidly absorbed with a Tmax of 3–4 h after the QD dose, and 2.5–9 h after the twice-daily (BID) dose. the word twice-daily ( ) has been deleted.

In page 2, in the text “AFN-1252 (given as a free base which is the active form of the drug)” the letter a has been deleted.

In page 2, in the text “All subjects were admitted to the clinic on day 0” the word day has been changed to Day.

In page 3, in abstract the unit ng h/ml should be changed to ng•h/ml throughout the article.

In page 5, in Table 2 the – should be changed to endash.

In page 7, below is the correct form of Table 4.

Table 4 Summary of treatment-emergent adverse events (TEAEs) in Part II (Cohorts 2–4)

Table

Preferred term, n (%)	Multiple dose
	Single dose Cohorts 2,3,4	Cohorts 2,3,4	Cohort 2	Cohort 3	Cohort 4	Overall
	Lead 200 mg (n = 24)	Placebo (n = 6)	200 mg (n = 6)	300 mg (n = 6)	400 mg (n = 6)	(n = 24)
Total number of TEAEs	7	2	3	15	7	27
Number of unique subjects with at least 1 TEAE	5	2	3	5	4	14
Headache	4	0	2	5	1	8
Dizziness	0	0	1	1	0	2
Presyncope	1	0	0	0	0	0
Arthralgia	0	0	0	2	0	2
Back pain	0	0	0	1	0	1
Musculoskeletal chest pain	0	0	0	1	0	1
Pain in extremity	0	0	0	0	1	1
Nausea	1	0	0	1	1	2
Oesophageal discomfort	0	0	0	1	0	1
Vomiting	0	0	0	0	1	1
Dermatitis contact	0	0	0	1	0	1
Dry skin	0	1	0	0	0	1
Eczema	0	0	0	0	1	1
Nasopharyngitis	0	0	0	0	1	1
Viral infection	0	0	0	1	0	1
Oropharyngeal pain	0	1	0	0	0	1

And there are a few more errors in the whole article. The updated version can be found in the article as follows.

http://dx.doi.org/10.1179/1973947815Y.0000000075

Taylor & Francis and The Authors apologise for these errors.